Astroblastoma

Astroblastoma is an extremely rare primary brain tumor of neuroepithelial origin that arises within the cerebral hemispheres. It is classified among glial tumors and is thought to originate from astroblasts, which are precursor cells of astrocytes. Astroblastomas are characterized histologically by distinctive perivascular pseudorosettes with broad, non-tapering cellular processes radiating toward blood vessels. The tumor predominantly affects children and young adults, with a slight female predominance reported in the literature. Astroblastomas are typically supratentorial and present as well-circumscribed masses, often with both solid and cystic components. Key symptoms depend on the tumor's location and size and commonly include headaches, seizures, focal neurological deficits, increased intracranial pressure, nausea, vomiting, and visual disturbances. Some patients may experience cognitive or behavioral changes. The tumor is graded into low-grade (well-differentiated) and high-grade (malignant or anaplastic) variants, which significantly influences prognosis. Low-grade astroblastomas generally carry a more favorable prognosis, while high-grade tumors are associated with a higher risk of recurrence and poorer outcomes. The primary treatment for astroblastoma is maximal safe surgical resection, which is considered the most important prognostic factor. Gross total resection is associated with significantly improved survival. The role of adjuvant radiation therapy and chemotherapy remains debated due to the rarity of the tumor and the lack of large clinical trials. Radiation therapy is often considered for high-grade tumors or cases with incomplete resection. Recent molecular studies have identified recurrent alterations, including MN1 gene rearrangements (particularly MN1-BEND2 fusions), which have helped refine the diagnosis and distinguish astroblastoma from other glial tumors. The WHO Classification of Tumors of the Central Nervous System has recognized MN1-altered astroblastoma as a distinct entity, aiding in more accurate diagnosis and potentially guiding future therapeutic strategies.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Astroblastoma